Abstract: The present invention relates among other things to a novel method of diagnosing cancer by applying antibodies that bind to human C1 inactivator, antibodies that bind to human C Reactive Protein and/or antibodies that bind to human Complement Component C4. Also the present invention relates to a pharmaceutical composition comprising one or more antibodies that bind to C inactivator, antibodies that bind to human C Reactive Protein and/or antibodies that bind to human Complement Component C4 for use in the treatment of cancer, inhibiting growth of cancer and/or inhibiting proliferation of cancer.

Abstract: The present invention relates to method of preparing an absorbent wound care device comprising an active agent on a wound contacting surface, such as e.g. a protein or an enzyme, by the use of electrospraying, and a wound care device obtained by said method. The invention further relates to a wound care device comprising Thrombin and a polyurethane foam, and a method of treating bleeding.

Abstract: The present invention relates to method of preparing an absorbent wound care device comprising an active agent on a wound contacting surface, such as e.g. a protein or an enzyme, by the use of electrospraying, and a wound care device obtained by said method. The invention further relates to a wound care device comprising Thrombin and a polyurethane foam, and a method of treating bleeding.

Abstract: Disclosed are methods and means for treatment of neurodegenerative disease. In particular, the methods entail administration of stem cells expressing genes encoding therapeutically effective amounts of Nrf2. Also disclosed is a gene-therapy method for treatment of neurodegenerative disease, where genes encoding Nrf2 are administered.

Abstract: The present invention discloses methods for the preparation of recombinant human proteins expressed in human cells. The present invention relates to methods for the preparation of human recombinant thrombin and human recombinant fibrinogen. The method employs serum-free culturing conditions and provides recombinant human proteins expressed in human cells of increased safety to the patient when used in human medical treatments. The immunogenic response to the recombinant human proteins expressed in human cells may be lower. Human recombinant thrombin is expressed in the human embryonic kidney 293 cell line and the protein can be prepared using two different routes, one starting from a point mutated prothrombin with gla and Kringle 1 and 2 domains, and maintaining these domains during the process; the other one starting with prothrombin (non-mutated), via a prethrombin with a HPC4-Kringle 2 domain and subjecting this prethrombin to a point mutation.

Abstract: Provided are novel post-translationally modified variants of fibrinogen, in particular human fibrinogen, a method for producing and isolating said variants, as well as methods of using the variant, in particular in systemic and local/topical treatment and prophylaxis of excessive bleeding.

Abstract: The present invention discloses a novel method for the preparation of recombinant human proteins expressed in human cells. Specifically, the present invention relates to novel methods for the preparation of human recombinant thrombin and human recombinant fibrinogen. Moreover, the method employs serum-free culturing conditions and therefore provides recombinant human proteins expressed in human cells of increased safety to the patient when used in human medical treatments. In addition, the immunogenic response to the recombinant human proteins expressed in human cells may be lower. Human recombinant thrombin is expressed in the human embryonic kidney 293 cell line and the protein can be prepared using two different routes, one starting from a point mutated prothrombin with gla and Kringle 1 and 2 domains, and maintaining these domains during the process; the other one starting with prothrombin (non-mutated), via a prethrombin with a HPC4-Kringle 2 domain and subjecting this prethrombin to a point mutation.

Abstract: The present invention provides for a method for tissue engineering by cell implantation that involves the use of a scaffold in situ at the site of a defect, where the therapeutic cells are fixed in place into the scaffold only once the scaffold is inserted at the site of the tissue defect, thereby locking not only the cells to the scaffold, but also the scaffold to the tissue defect. The invention also provides a kit of parts suitable for performing the method of the invention.

Abstract: The present invention relates to a method for propagating and/or differentiating mammalian cells, the method comprising exposing or co-culturing mammalian cells with one or more of periodontal ligament tissue, periodontal ligament proteins or factors derived from periodontal ligament tissue, to obtain cells having PDL characteristics and fulfilling at least one of the following: i) show periodontal characteristics as evidenced with Von Kossa method in which calcium phosphate deposits are stained brown to black, ii) show increased osteopontin and osteocalcin and at the same time decreased bone sialoprotein (bone sialoprotein II or BSP), iii) are capable of being implanted to repair and/or regenerate periodontal tissue, iv) are capable of repairing disorders such as paradentitis also called paradentosis, or periodontitis by healing of the gum line towards the teeth, and v) are accepted by the host without significant immune reaction or cell rejection.

Abstract: An endoscopic method for treating cartilage or bone defects in an animal, said method comprising the steps of: I) identifying the position of the defect, ii) applying cells selected from the group consisting of chondrocytes, chondroblasts, osteocytes and osteoblasts and combinations thereof into the cartilage or bone defect.

Abstract: Method for the effective transplantation of chondrocytes/cartilage to an articular joint surface defect is taught, as well as a description of certain instruments and kit for practicing the invention.

Abstract: A production method for producing cell colony forming units in vitro from a mammalian tissue explant, the method comprises the steps of a) growing a piece of the mammalian tissue explant in a growth medium to obtain cell colony forming units from immature cells from the piece of explant, and b) harvesting cells from one or more of the cell colony forming units for use in Autologous Cell Implantation/transplantation methods. The mammalian tissue explant is selected from the group consisting of cartilage; bone such as, e.g., bone marrow; connective tissue; muscle tissue such as, e.g., smooth muscle tissue, heart tissue, liver tissue and skeletal muscle tissue; skin tissue such as, e.g., periosteum; mucosal tissue; brain tissue, pancreas tissue and blood vessels. In particularly, the mammalian tissue explant is cartilage, such as elastic, fibro, hyalin or articular hyalin cartilage. The cells obtained are suitable for use in autologous implantation/transplantation methods.

Abstract: The present invention relates to methods and materials for in vivo repair of cartilage or bone and cartilage defects in mammals. The invention relates to membranes carrying a composition comprising at least one stimulation molecule, which is capable of inducing signal transduction in chondroblasts/chondrocytes and/or osteoblasts/osteocytes. Furthermore the invention relates to a method for the preparation of chondroblasts/chondrocytes and/or osteoblasts/osteocytes suspensions.